Table 1.
Relationship between clinicopathologic characteristics and the expression of CD10 and CD15 in 515 patients with papillary thyroid carcinoma.
| n | CD10 Expression | CD15 Expression | |||||
|---|---|---|---|---|---|---|---|
| Positive | Negative | p Value | Positive | Negative | p Value | ||
| Age (years) | 0.772 | 0.233 | |||||
| <55 | 365 | 141 (38.6%) | 224 (61.4%) | 203 (55.6%) | 162 (44.4%) | ||
| ≥55 | 150 | 60 (40.0%) | 90 (60.0%) | 92 (61.3%) | 58 (38.7%) | ||
| Sex | 0.049 | 0.009 | |||||
| Female | 405 | 167 (41.2%) | 238 (58.8%) | 244 (60.2%) | 161 (39.8%) | ||
| Male | 110 | 34 (30.9%) | 76 (69.1%) | 51 (46.4%) | 59 (53.6%) | ||
| Histologic type | 0.009 | 0.002 | |||||
| Classic | 453 | 174 (38.4%) | 279 (61.6%) | 260 (57.4%) | 193 (42.6%) | ||
| Follicular variant | 17 | 2 (11.8%) | 15 (88.2%) | 3 (17.6%) | 14 (82.4%) | ||
| Tall cell variant | 21 | 10 (47.6%) | 11 (52.4%) | 15 (71.4%) | 6 (28.6%) | ||
| Other | 24 | 15 (62.5%) | 9 (37.5%) | 17 (70.8%) | 7 (29.2%) | ||
| Extrathyroidal extension | |||||||
| Absent | 137 | 38 (27.7%) | 99 (72.3%) | 64 (46.7%) | 73 (53.3%) | ||
| Minimal * | 279 | 120 (43.0%) | 159 (57.0%) | 0.003 | 166 (59.5%) | 113 (40.5%) | 0.014 |
| Gross | 99 | 43 (43.4%) | 56 (56.6%) | 0.317 | 65 (65.7%) | 34 (34.3%) | 0.061 |
| Pathological (p) T stage | 0.164 | 0.181 | |||||
| pT1 | 357 | 129 (36.1%) | 228 (63.9%) | 197 (55.2%) | 160 (44.8%) | ||
| pT2 | 56 | 27 (48.2%) | 29 (51.8%) | 30 (53.6%) | 26 (46.4%) | ||
| pT3 | 81 | 34 (42.0%) | 47 (58.0%) | 55 (67.9%) | 26 (32.1%) | ||
| pT4 | 20 | 10 (50.0%) | 10 (50.0%) | 12 (60.0%) | 8 (40.0%) | ||
| Lymph node metastasis | 0.143 | 0.735 | |||||
| Absent | 197 | 69 (35.0%) | 128 (65.0%) | 111 (56.3%) | 86 (43.7%) | ||
| Present | 318 | 132 (41.5%) | 186 (58.5%) | 184 (57.9%) | 134 (42.1%) | ||
| Distant metastasis | 0.286 | 0.062 | |||||
| Absent | 504 | 195 (38.7%) | 309 (61.3%) | 292 (57.9%) | 212 (42.1%) | ||
| Present | 11 | 6 (54.5%) | 5 (45.5%) | 3 (27.3%) | 8 (72.7%) | ||
| AJCC stage 8th | 0.229 | 0.646 | |||||
| Stage I | 421 | 160 (38.0%) | 261 (62.0%) | 240 (57.0%) | 181 (43.0%) | ||
| Stage II | 81 | 34 (42.0%) | 47 (58.0%) | 49 (60.5%) | 32 (39.5%) | ||
| Stage III | 9 | 5 (55.6%) | 4 (44.4%) | 6 (66.7%) | 3 (33.3%) | ||
| Stage IV | 4 | 2 (50.0%) | 2 (50.0%) | 0 | 4 (100.0%) | ||
| Recurrence | 0.656 | 0.034 | |||||
| Absent | 461 | 179 (38.8%) | 282 (61.2%) | 270 (58.6%) | 191 (41.4%) | ||
| Present | 45 | 19 (42.2%) | 26 (57.8%) | 19 (42.2%) | 26 (57.8%) | ||
| BRAF V600E | 0.011 | <0.001 | |||||
| Absent | 83 | 22 (26.5%) | 61 (73.5%) | 13 (15.7%) | 70 (84.3%) | ||
| Present | 432 | 179 (41.4%) | 253 (58.6%) | 282 (65.3%) | 150 (34.7%) | ||
AJCC, American Joint Committee on Cancer. The AJCC 8th edition cancer staging was used in this study. * Minimal extrathyroidal extension by AJCC 8th edition refers to the extension to perithyroid adipose tissue, strap muscles, nerves, or small vascular structures identified only by microscopic examination [27].